Fate Therapeutics
Skip to content
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
    • Early/Expanded Access Policy
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Vision, Mission, Values
    • Working at Fate
    • Career Opportunities
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact

One Cell. Many Fates.

Transforming the lives of patients with cancer and immune disorders

  • FT500
  • FT516
  • FT596
  • FT538
  • FT576
  • FT819
  • ProTmune™
  • FT573
  • Press Releases

©2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGAL

  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
    • Early/Expanded Access Policy
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Vision, Mission, Values
    • Working at Fate
    • Career Opportunities
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact